InMed Pharmaceuticals (INM) Other Non Operating Income (2019 - 2026)
InMed Pharmaceuticals' (INM) quarterly Other Non Operating Income came in at -$23168.0 in Q1 2026, down 4.53% year-on-year from -$24266.1 in Q1 2025, and down 227.75% quarter-over-quarter from $18136.0 in Q4 2025.
InMed Pharmaceuticals (INM) Other Non Operating Income (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Other Non Operating Income history runs 8 years deep, the most recent figure standing at -$23168.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 4.53% year-over-year to -$23168.0 in Q1 2026; TTM through Mar 2026 was -$39889.0, a 47.38% increase from a year earlier, with the FY2025 full-year figure at -$28471.0, up 54.02% from the prior year.
- Other Non Operating Income fell to -$23168.0 in Q1 2026 per INM's latest filing, from $18136.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $59896.0 in Q4 2023 and bottomed at -$96791.0 in Q3 2022.
- The 5-year median for Other Non Operating Income is -$22165.0 (2025), against an average of -$13943.5.
- Across the five-year window, Other Non Operating Income surged 573.0% in 2022 and sank 1662.02% in 2024, its largest moves.
- Year by year, Other Non Operating Income stood at $20237.0 in 2022, then surged by 195.97% to $59896.0 in 2023, then sank by 179.73% to -$47753.0 in 2024, then surged by 137.98% to $18136.0 in 2025, then sank by 227.75% to -$23168.0 in 2026.
- Per Business Quant, the three latest INM Other Non Operating Income figures stand at -$23168.0 (Q1 2026), $18136.0 (Q4 2025), and -$56994.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23,168.00 |
| Dec 31, 2025 | 18,136.00 |
| Sep 30, 2025 | -56,994.00 |
| Jun 30, 2025 | 22,137.00 |
| Mar 31, 2025 | -22,165.00 |
| Dec 31, 2024 | -47,753.00 |
| Sep 30, 2024 | 19,310.00 |
| Jun 30, 2024 | -25,204.00 |
| Mar 31, 2024 | -48,156.00 |
| Dec 31, 2023 | 59,896.00 |
| Sep 30, 2023 | -48,457.00 |
| Jun 30, 2023 | 31,112.00 |
| Mar 31, 2023 | -2,733.00 |
| Dec 31, 2022 | 20,237.00 |
| Sep 30, 2022 | -96,791.00 |
| Jun 30, 2022 | -69,442.00 |
| Mar 31, 2022 | 32,996.00 |
| Dec 31, 2021 | 3,007.00 |
| Sep 30, 2021 | -84,112.00 |
| Jun 30, 2021 | -187,815.00 |